-
公开(公告)号:US20080167194A1
公开(公告)日:2008-07-10
申请号:US11929793
申请日:2007-10-30
IPC分类号: C40B10/00
CPC分类号: C07K1/047 , B01J2219/007 , C07K1/063 , C12N9/86 , C12N15/102 , C12N15/1027 , C12N15/1044 , C12N15/1089 , C12Y305/02006 , C40B30/04 , G01N33/6845 , G16B15/00 , G16B40/00
摘要: The invention relates to the use of protein design automation (PDA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.
摘要翻译: 本发明涉及使用蛋白质设计自动化(PDA)来生成计算预先筛选的蛋白质二级文库,以及利用文库的方法和组合物。
-
公开(公告)号:US06403312B1
公开(公告)日:2002-06-11
申请号:US09419351
申请日:1999-10-15
IPC分类号: C12Q168
CPC分类号: C12Y305/02006 , C12N9/86 , C12N15/102 , C12N15/1034
摘要: The invention relates to the use of protein design automaton (PDA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.
摘要翻译: 本发明涉及使用蛋白质设计自动机(PDA)来生成计算预先筛选的蛋白质二级文库,以及利用文库的方法和组合物。
-
公开(公告)号:US07315786B2
公开(公告)日:2008-01-01
申请号:US09927790
申请日:2001-08-10
CPC分类号: C07K1/047 , B01J2219/007 , C07K1/063 , C12N9/86 , C12N15/102 , C12N15/1027 , C12N15/1044 , C12N15/1089 , C12Y305/02006 , C40B30/04 , G01N33/6845 , G06F19/16 , G06F19/24
摘要: The invention relates to the use of protein design automation (P DA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.
摘要翻译: 本发明涉及使用蛋白质设计自动化(P DA)来生成计算预先筛选的蛋白质二级文库,以及利用文库的方法和组合物。
-
公开(公告)号:US07379822B2
公开(公告)日:2008-05-27
申请号:US10666311
申请日:2003-09-18
摘要: The invention relates to the use of protein design automation (PDA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.
摘要翻译: 本发明涉及使用蛋白质设计自动化(PDA)来生成计算预先筛选的蛋白质二级文库,以及利用文库的方法和组合物。
-
公开(公告)号:US20100234573A1
公开(公告)日:2010-09-16
申请号:US12697945
申请日:2010-02-01
申请人: Aaron Keith Chamberlain , Bassil I. Dahiyat , John R. Desjarlais , Sher Bahadur Karki , Gregory Alan Lazar
发明人: Aaron Keith Chamberlain , Bassil I. Dahiyat , John R. Desjarlais , Sher Bahadur Karki , Gregory Alan Lazar
IPC分类号: C07K16/00
CPC分类号: C07K16/18 , A61K2039/505 , C07K14/7151 , C07K16/082 , C07K16/22 , C07K16/241 , C07K16/2863 , C07K16/2866 , C07K16/2893 , C07K16/2896 , C07K16/32 , C07K16/4291 , C07K2317/24 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/90 , C07K2319/30 , Y02A50/484
摘要: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
摘要翻译: 本申请涉及包含相对于野生型人Fc区的至少一个修饰的变体Fc区,其中选自434S,252Y / 428L,252Y / 434S和428L / 434S的修饰,以及 编号是根据欧盟指数。
-
公开(公告)号:US20080267979A1
公开(公告)日:2008-10-30
申请号:US12089957
申请日:2006-10-11
申请人: Gregory Alan Lazar , Bassil I. Dahiyat , Hisafumi Okabe , Masamichi Sugimoto , Shigeyuki Iijima , Izumi Sugo
发明人: Gregory Alan Lazar , Bassil I. Dahiyat , Hisafumi Okabe , Masamichi Sugimoto , Shigeyuki Iijima , Izumi Sugo
IPC分类号: A61K39/395 , C12P21/08 , C07K16/18 , A61P35/00
CPC分类号: C07K16/303 , A61K2039/505 , C07K2317/24 , C07K2317/72 , C07K2317/732
摘要: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
摘要翻译: 公开了包含在Fc区中引入的一个或多个氨基酸取代的抗磷脂酰肌醇蛋白聚糖-3抗体。 优选地,在抗磷脂酰肌醇蛋白聚糖-3抗体中,Fc区中位置239,298,326,330和332处的一个或多个氨基酸残基被其它氨基酸残基取代。 由于本发明的Fc修饰的抗磷脂酰肌醇蛋白聚糖-3抗体表现出增强的ADCC活性,因此可用于治疗诸如肝癌的癌症。 还公开了包含本发明的抗磷脂酰肌醇蛋白聚糖-3抗体和药学上可接受的载体的抗癌剂,以及治疗患有癌症的患者的方法,包括向患者施用本发明的抗癌剂。
-
公开(公告)号:US06950754B2
公开(公告)日:2005-09-27
申请号:US09812034
申请日:2001-03-19
IPC分类号: C12N15/09 , C07K1/00 , C07K14/00 , C12N1/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/10 , G06F17/50 , G06F19/16 , G06F19/18 , G06F19/22 , G01N33/48 , G01N31/00
CPC分类号: C12N15/1089 , C07K1/00 , C07K1/003 , C07K14/001 , C12N15/1034 , G06F19/16 , G06F19/18 , G06F19/22
摘要: The present invention relates to apparatus and methods for quantitative protein design and optimization.
-
公开(公告)号:US06269312B1
公开(公告)日:2001-07-31
申请号:US09127926
申请日:1998-07-31
IPC分类号: G01N3348
CPC分类号: C12N15/1089 , C07K1/00 , C07K1/003 , C07K14/001 , C12N15/1034 , G06F19/16 , G06F19/18 , G06F19/22
摘要: The present invention relates to apparatus and methods for quantitative protein design and optimization.
-
公开(公告)号:US08637641B2
公开(公告)日:2014-01-28
申请号:US13194904
申请日:2011-07-29
CPC分类号: C07K16/22 , A61K2039/505 , C07H21/00 , C07K16/00 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/94
摘要: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
摘要翻译: 本发明一般涉及用于改变抗体的等电点的组合物和方法,并且在一些情况下导致改善的血浆药代动力学,例如, 增加体内血清半衰期。
-
公开(公告)号:US08367805B2
公开(公告)日:2013-02-05
申请号:US12341769
申请日:2008-12-22
申请人: Aaron Keith Chamberlain , Bassil I. Dahiyat , John R. Desjarlais , Sher Bahadur Karki , Gregory Alan Lazar
发明人: Aaron Keith Chamberlain , Bassil I. Dahiyat , John R. Desjarlais , Sher Bahadur Karki , Gregory Alan Lazar
IPC分类号: C07K16/00 , C12P218/08 , A61K39/395 , A61K39/40 , A61K39/42 , C07K1/00
CPC分类号: C07K16/18 , A61K2039/505 , C07K14/7151 , C07K16/082 , C07K16/22 , C07K16/241 , C07K16/2863 , C07K16/2866 , C07K16/2893 , C07K16/2896 , C07K16/32 , C07K16/4291 , C07K2317/24 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/90 , C07K2319/30 , Y02A50/484
摘要: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
摘要翻译: 本申请涉及包含相对于野生型人Fc区的至少一个修饰的变体Fc区,其中选自434S,252Y / 428L,252Y / 434S和428L / 434S的修饰,以及 编号是根据欧盟指数。
-
-
-
-
-
-
-
-
-